Physiological testosterone replacement therapy attenuates fatty streak formation and improves high-density lipoprotein cholesterol in the Tfm mouse: An effect that is independent of the classic androgen receptor

Circulation

Volumn 116, Issue 21, 2007, Pages 2427-2434

  Nettleship, Joanne E ^a   Jones, T Hugh ^a,b   Channer, Kevin S ^c   Jones, Richard D ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b BARNSLEY HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^c SHEFFIELD HALLAM UNIVERSITY   (United Kingdom)

Author keywords

Atherosclerosis; Cholesterol; Hormones; Lesion

Indexed keywords

ANASTROZOLE; ANDROGEN RECEPTOR; AROMATASE INHIBITOR; ESTRADIOL; FULVESTRANT; HIGH DENSITY LIPOPROTEIN; PLACEBO; SODIUM CHLORIDE; TESTOSTERONE;

ADJUVANT THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA ROOT; ARTICLE; ATHEROMA; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL DIET; CONTROLLED STUDY; HORMONE SUBSTITUTION; HYPOTESTOSTERONEMIA; KARYOTYPE 46,XY; LIPID STORAGE; MALE; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; STATISTICAL SIGNIFICANCE; TESTICULAR FEMINIZATION; TESTOSTERONE BLOOD LEVEL;

ANIMALS; ATHEROSCLEROSIS; CHOLESTEROL, HDL; HORMONE REPLACEMENT THERAPY; MALE; MICE; MICE, MUTANT STRAINS; RECEPTORS, ANDROGEN; TESTOSTERONE;

EID: 36348969504     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.107.708768     Document Type: Article

References (42)

1. Bagatell CJ, Bremner WJ. Androgens in men: uses and abuses. The N Engl J Med. 1996;334:707-714.
2. British Heart Foundation Statistics Database. Available at http://www.bhf.org.uk. Accessed February 2007.
3. Jones RD, Nettleship JE, Kapoor DE, Jones TH, Channer KS. Testosterone and atherosclerosis in aging men. Am J Cardiovasc Drugs. 2005;5:141-154.
4. Larsen BA, Nordestgaard BG, Stender S, Kjeldsen K. Effect of testosterone on atherogenesis in cholesterol-fed rabbits with similar plasma-cholesterol levels. Atherosclerosis. 1993;99:79-86.
5. Bruck B, Brehme U, Gugel N, Hanke S, Finking G, Lutz C, Benda N, Schmahl FW, Haasis R, Hanke H. Gender-specific differences in the effects of testosterone and estrogen on the development of atherosclerosis in rabbits. Arterioscler Thromb Vasc Biol. 1997;17:2192-2199.
6. Alexandersen P, Haarbo J, Byrjalsen I, Lawaetz H, Christiansen C. Natural androgens inhibit male atherosclerosis: a study in castrated, cholesterol-fed rabbits. Circ Res. 1999;84:813-819.
7. Nathan L, Shi WB, Dinh H, Mukherjee TK, Wang XP, Lusis AJ, Chaudhuri G. Testosterone inhibits early atherogenesis by conversion to estradiol: critical role of aromatase. Proc Natl Acad Sci U S A. 2001;98:3589-3593.
8. Gordon GB, Bush DE, Weisman HF. Reduction of atherosclerosis by administration of dehydroepiandrosterone: a study in the hypercholesterolemic New Zealand White rabbit with aortic intimal injury. J Clin Invest. 1988;82:712-720.
9. Arad Y, Badimon JJ, Badimon L, Hembree WC, Ginsberg HN. Dehydroepiandrosterone feeding prevents aortic fatty streak formation and cholesterol accumulation in cholesterol-fed rabbit. Arterioscler Thromb. 1989;9:159-166.
10. Eich DM, Nestler JE, Johnson DE, Dworkin GH, Ko D, Wechsler AS, Hess ML. Inhibition of accelerated coronary atherosclerosis with dehydroepiandrosterone in the heterotopic rabbit model of cardiac transplantation. Circulation. 1993;87:261-269.
11. Hanke H, Lenz C, Spindler KD, Weidemann W. Effect of testosterone on plaque development and androgen receptor expression in the arterial vessel wall. Circulation. 2001;103:1382-1385.
12. von Dehn G, von Dehn O, Volker W, Langer C, Weinbauer GF, Behre HM, Nieschlag E, Assmann G, von Eckardstein A. Atherosclerosis in apolipoprotein E-deficient mice is decreased by the suppression of endogenous sex hormones. Horm Metab Res. 2001;33:110-114.
13. Jones RD, English KM, Pugh PJ, Morice AH, Jones TH, Channer KS. Pulmonary vasodilatory action of testosterone: evidence of a calcium antagonistic action. J Cardiovasc Pharmacol. 2002;39:814-823.
14. 2+ channels in A7r5 cells by physiological levels of testosterone. Endocrinology. 2006;147:2675-2680.
15. Gorczynska E, Handelsman DJ. Androgens rapidly increase the cytosolic calcium concentration in Sertoli cells. Endocrinology. 1995;136:2052-2059.
16. Guo Z, Benten WPM, Krucken J, Wunderlich F. Non-genomic testosterone calcium signaling: genotropic actions in androgen receptor-free macrophages. J Biol Chem. 2002;277:29600-29607.
17. Lieberherr M, Grosse B. Androgens increase intracellular calcium concentration and inositol 1,4,5-trisphosphate and diacylglycerol formation via a pertussis toxin-sensitive G-protein. J Biol Chem. 1994;269:7217-7223.
18. Steinsapir J, Socci R, Reinach P. Effects of androgen on intracellular calcium of LNCaP cells. Biochem Biophys Res Commun. 1991;179:90-96.
19. Charest NJ, Zhou ZX, Lubahn DB, Olsen KL, Wilson EM, French FS. A frameshift mutation destabilizes androgen receptor messenger RNA in the Tfm mouse. Mol Endocrinol. 1991;5:573-581.
20. He WW, Kumar MV, Tindall DJ. A frame-shift mutation in the androgen receptor gene causes complete androgen insensitivity in the testicular-feminized mouse. Nucleic Acids Res. 1991;19:2373-2378.
21. Jones RD, Pugh PJ, Hall J, Channer KS, Jones TH. Altered circulating hormone levels, endothelial function and vascular reactivity in the testicular feminised mouse. Eur J Endocrinol. 2003;148:111-120.
22. Murphy L, O'Shaughnessy PJ. Testicular steroidogenesis in the testicular feminized (Tfm) mouse: loss of 17-alpha-hydroxylase activity. J Endocrinol. 1991;131:443-449.
23. Nettleship JE, Jones RD, Channer KS, Jones TH. Cholesterol feeding induces fatty streak formation in the testicular feminised mouse. Endocr Abstracts. 2005;9:P19.
24. English KM, Mandour O, Steeds RP, Diver MJ, Jones TH, Channer KS. Men with coronary artery disease have lower levels of androgens than men with normal coronary angiograms. Eur Heart J. 2000;21:890-894.
25. Kabakci G, Yildirir A, Can I, Unsal I, Erbas B. Relationship between endogenous sex hormone levels, lipoproteins and coronary atherosclerosis in men undergoing coronary angiography. Cardiology. 1999;92:221-225.
26. Phillips G, Pinkernell B, Jing T. The association of hypotestosteronemia with coronary artery disease in men. Arterioscler Thromb. 1994;14:701-706.
27. Pugh PJ, Channer KS, Parry H, Downes T, Jones TH. Bio-available testosterone levels fall acutely following myocardial infarction in men: association with fibrinolytic factors. Endocr Res. 2002;28:161-173.
28. Zhao SP, Li XP. The association of low plasma testosterone level with coronary artery disease in Chinese men. Int J Cardiol. 1998;63:161-164.
29. Barrett-Connor E, Khaw K. Endogenous sex hormones and cardiovascular disease in men: a prospective population-based study. Circulation. 1988;78:539-545.
30. Barrett-Connor E. Lower endogenous androgen levels and dyslipidemia in men with non-insulin-dependent diabetes mellitus. Ann Intern Med. 1992;117:807-811.
31. Haffner S, Mykkanen L, Valdez R, Katz M. Relationship of sex hormones to lipids and lipoproteins in non-diabetic men. J Clin Endocrinol Metab. 1993;77:1610-1615.
32. Barud W, Palusinski R, Beltowski J, Wojcicka G. Inverse relationship between total testosterone and anti-oxidized low density lipoprotein antibody levels in ageing males. Atherosclerosis. 2002;164:283-288.
33. Simon D, Charles M, Nahoul K, Orssaud G, Kremski J, Hully V, Joubert E, Papoz L, Eschwege E. Association between plasma total testosterone and cardiovascular risk factors in healthy adult men: the Telecom Study. J Clin Endocrinol Metab. 1997;82:682-685.
34. Malkin CJ, Pugh PJ, Jones RD, Kapoor D, Channer KS, Jones TH. The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profiles in hypogonadal men. J Clin Endocrinol Metab. 2004;89:3313-3318.
35. Kapoor D, Goodwin E, Channer KS, Jones TH. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol. 2006;6:899-906.
36. Van Pottelbergh I, Braeckman L, De Bacquer D, De Backer G, Kaufman J. Differential contribution of testosterone and estradiol in the determination of cholesterol and lipoprotein profile in healthy middle-aged men. Atherosclerosis. 2003;166:95-102.
37. Stanworth R, Kapoor D, Channer KS, Jones TH. HDL cholesterol levels are positively associated with testosterone and are lower with shorter androgen receptor CAG repeat lengths in men with type 2 diabetes. Endocr Abstracts. 2007;13:P258.
38. Shono N, Kumagai S, Higaki Y, Nishizumi M, Sasaki H. The relationship of testosterone, estradiol, dehydroepiandrosterone-sulphate and sex hormone binding globulin to lipid and glucose metabolism in healthy men. J Atheroscler Thromb. 1996;3:45-51.
39. Dai W, Gutai J, Kuller L, Laporte R, Falvo-Gerald L, Caggiula A. A relationship between plasma high-density lipoprotein cholesterol and sex hormone concentrations in men. Am J Cardiol. 1994;53:1259-1263.
40. Scragg J, Dallas M, Peers C. Molecular requirements for L-type Ca2 channel blockade by testosterone. Cell Calcium. 2006;42:11-15.
41. Henry P, Bentley K. Suppression of atherogenesis in cholesterol-fed rabbit treated with nifedipine. J Clin Invest. 1981;5:1366-1369.
42. Lesnik P, Dachet C, Petit L, Moreau M, Griglio S, Brudi P, Chapman MJ. Impact of a combination of a calcium antagonist and a β-blocker on cell- and copper-mediated oxidation of LDL and on the accumulation and efflux of cholesterol in human macrophages and murine J774 cells. Arterioscler Thromb Vasc Biol. 1997;17:979-988.